logo-loader
viewOpen Orphan PLC

Open Orphan signs UK government contract to development COVID-19 Human Challenge Study Model

Open Orphan's (LON:ORPH) Chairman Cathal Friel talks to Proactive London after announcing a contract with the UK Government for the development of a COVID-19 human challenge study model.

Friel explains that the company, hVIVO, is the world's leader in this sector, having safely run more human challenge studies than any other company globally.

The contract starts immediately and could be worth approximately £10 million to hVIVO depending upon the final number of volunteers that are included in the characterisation study.

He explains that the Government has secured the first three slots to test vaccines using hVIVO's COVID-19 challenge study, which he expects to start in 2021, at a cost of £2.5m each bringing the total value of these slot reservations to £7.5m.

Quick facts: Open Orphan PLC

Price: 25 GBX

AIM:ORPH
Market: AIM
Market Cap: £166.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan present at the Proactive One2one virtual investment forum

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 week, 4 days ago

2 min read